Has Eric Mullins received payments from drug or device companies?

Yes. Drug and device makers reported $77,650 in general payments to Eric Mullins across 69 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Eric Mullins did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Eric Mullins come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Eric Mullins

Pediatric Hematology-Oncology · Cincinnati, OHNPI 1225238389

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $70,333 of the $77,650 with a category attached, or 90.6%. 5 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 42.5% of the total. Among pediatric hematology-oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$77,650in general payments, 2019–2025

Across 69 payments — averaging $1125.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$33K
Novo Nordisk$29K
Shire North American Group Inc$13K
HEMA Biologics, LLC$3K
Genentech USA, Inc.$298

$386,104in research payments, 2019–2025

Across 226 payments — averaging $1708.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$184K
Shire North American Group Inc$115K
Novo Nordisk AS$69K
Spark Therapeutics, Inc.$18K

What the payments were for

Consulting fees$70,33391%
Travel & lodging$5,6097%
Food & beverage$1,6912%
Education$60%
Gifts$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	27	$33,003
Novo Nordisk	15	$29,192
Shire North American Group Inc	18	$12,638
HEMA Biologics, LLC	7	$2,520
Genentech USA, Inc.	2	$298

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ADVATE$12,507
ADYNOVATE$5,532
FEIBA$4,307
SevenFact$2,500
HEMLIBRA$149

How this compares

$77,650 in reported general payments places this provider in the 95th percentile of 143 pediatric hematology-oncology providers in Ohio.

See all pediatric hematology-oncology providers in Ohio →

Other pediatric hematology-oncology in Cincinnati

Ashish KumarCincinnati$420K
Sonata JodeleCincinnati$113K
Russell WareCincinnati$83K
Christopher DandoyCincinnati$78K
Pooja KhandelwalCincinnati$69K
Michael JordanCincinnati$61K
Michael GrimleyCincinnati$51K
Cristina TarangoCincinnati$34K
Anthony SabulskiCincinnati$32K
Adrienne HammillCincinnati$25K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →